Loading
VISION was the trial that established radioligand therapy in prostate cancer.
VISION, trial NCT03511664 sponsored by Novartis and published in the New England Journal of Medicine in 2021, was the trial that established radioligand therapy in prostate cancer. It randomised 831 men with PSMA-positive metastatic castration-resistant prostate cancer after an androgen receptor pathway inhibitor and a taxane to 177Lu-PSMA-617 plus standard care or standard care alone, selected by PSMA PET, and met both primary endpoints of overall and radiographic progression-free survival. Whether radioligand therapy should now be given before chemotherapy or even at diagnosis, as PSMAfore and PSMAddition test, is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
861 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | 177Lu-PSMA-617 + standard care | 551 | 15.3 months | 0.62 (0.52 to 0.74) | <0.001 | link |
| Standard care | 280 | 11.3 months | ||||
| Radiographic progression-free survivalprimary | 177Lu-PSMA-617 + standard care | - | 8.7 months | 0.4 (0.29 to 0.57) | <0.001 | link |
| Standard care | - | 3.4 months |
Shares Total-body PET for personalised radioligand dosing, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Novartis.
Shares TheraP (ANZUP 1603), VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, PSMA, PSMA PET.
Shares VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
Shares TheraP (ANZUP 1603), Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
Shares ALSYMPCA, PEACE-3 (EORTC 1333), What follows what in castration-resistant prostate cancer, Prostate cancer drugs in England: what NICE recommends, and what it refuses.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares PEACE-3 (EORTC 1333), CARD, mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer), What follows what in castration-resistant prostate cancer.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).